MediGene to Present at the BIO CEO & Investor Conference in New York

Internet live webcast on February 13, 2007 available at www.medigene.de

Martinsried/Munich, February 8, 2007. Today, the biotech company MediGene (Frankfurt, Prime Standard: MDG) announced that the company will be presenting at the BIO CEO & Investor Conference in New York, on February 13, 12:00 a.m. local time, at the Waldorf Astoria Hotel. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, will give a review of the company and update the audience on current business developments. The presentation will be available on the internet at www.medigene.com from February 13 on.

MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard®). A second drug (Polyphenon® E Ointment) has been approved by the FDA, the MAA for a third drug, Oracea®, is under review in several European countries. Several other drug candidates are in clinical development. In addition, MediGene owns cutting-edge platform technologies with the EndoTAG™, oncolytic HSV and mTCR (soluble T-cell receptor) technologies. The company’s core competence lies in research and development of novel approaches in anti cancer and autoimmune therapies. The drug candidate EndoTAG™-1 (clinical phase II in pancreatic cancer) aims at “starving out” tumors by destroying the supplying blood vessels. It builds on the successful new therapeutic principle of anti-angiogenesis (inhibition of vascularization), and yet provides an innovative variation thanks to its novel mode of action (vascular disruptive agent). RhuDex® is the first oral CD80 interactor and is developed for the treatment of rheumatoid arthritis. MediGene’s innovative oncolytic HSV (herpes simplex viruses) (phase I/II in glioma and liver metastases) are modified for the selective destruction of tumor cells without harming healthy tissue.

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. EndoTAGTM-1 and the MediGeneTM Logo are trademarks of MediGene AG, RhuDex® is a trademark of Avidex Ltd., Polyphenon E® is a trademark of Mitsui Norin, Oracea® is a trademark of CollaGenex, Inc.

Contact Information

Georg Dönges

Public Relations

MediGene AG

Contact via E-mail